Response to Letter to the Editor by Corinna Weber-Schoendorfer, PhD, MD, and Christof Schaefer, PhD, MD

Reproductive Toxicology 25 (2008) 392

Contents lists available at ScienceDirect

Reproductive Toxicology journal homepage: www.elsevier.com/locate/reprotox

Correspondence

Response to Letter to the Editor by Corinna WeberSchoendorfer, PhD, MD, and Christof Schaefer, PhD, MD We thank Dr. Weber-Schoendorfer and colleagues for their enlightening update. This shows how critical it is to continue, follow and report on new agents used in pregnancy. It also demonstrates the central role of this journal in clinical teratology. Dr. Weber-Scoenfelder and colleagues state that metastatic breast cancer in pregnancy is rare. We wish to draw their attention to the fact that the odds ratio for metastatic breast cancer in pregnancy is 2.5 as compared to matched non-pregnant women [1]. Unfortunately this statistics shows itself repeatedly in our Motherisk-Cancer in Pregnancy focus [2]. References [1] Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Burke B, Suttcliffe SB, et al. Maternal and fetal outcome after breast cancer in pregnancy. Am J Obstet Gynecol 1992;166:781–7. [2] http://www.motherisk.org.

0890-6238/$ – see front matter © 2008 Published by Elsevier Inc. doi:10.1016/j.reprotox.2008.02.003

Gideon Koren a,b,c,∗ Facundo Bournissen a,b Alon Shrim a,b a The Motherisk Program, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada M5G 1X8 b The University of Toronto, Canada c The University of Western Ontario, Canada ∗ Corresponding

author. Tel.: +1 416 813 1500x7413; fax: +1 416 813 7562. E-mail address: [email protected] (G. Koren) 4 February 2008 Available online 29 February 2008